<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33135196</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-2559</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>79</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Histopathology</Title>
          <ISOAbbreviation>Histopathology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Oncocytic intraductal carcinoma of salivary glands: a distinct variant with TRIM33-RET fusions and BRAF V600E mutations.</ArticleTitle>
        <Pagination>
          <StartPage>338</StartPage>
          <EndPage>346</EndPage>
          <MedlinePgn>338-346</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/his.14296</ELocationID>
        <Abstract>
          <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Salivary gland intraductal carcinoma (IDC) is a complex ductal neoplasm surrounded by a layer of myoepithelial cells. Recent insights have shown that there are three different types: intercalated duct-like, with frequent NCOA4-RET fusions; apocrine, with salivary duct carcinoma-like mutations; and mixed intercalated duct-like/apocrine, with RET fusions, including TRIM27-RET. In addition, an oncocytic IDC has been described, but it remains unclear whether it represents a fourth variant or simply oncocytic metaplasia of another IDC type. Our aim was to more completely characterize oncocytic IDC.</AbstractText>
          <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Six IDCs with oncocytic changes were retrieved from the authors' archives, from three men and three women ranging in age from 45 to 75 years (mean, 63 years). Five arose in the parotid gland, with one in an accessory parotid gland. Four patients with follow-up were free of disease after 1-23 months. Several immunostains (S100, mammaglobin, androgen receptor, and p63/p40) and molecular tools (RNA sequencing, RET fluorescence in-situ hybridisation, BRAF V600E VE1 immunohistochemistry, and Sanger sequencing) were applied. Histologically, the tumours were variably cystic with solid intracystic nodules often difficult to recognise as intraductal. In all, tumour ducts were positive for S100 and mammaglobin, negative for androgen receptor, and completely surrounded by myoepithelial cells positive for p63/p40. Molecular analysis revealed TRIM33-RET in two of six cases, NCOA4-RET in one of six cases, and BRAF V600E in two of six cases. One case had no identifiable alterations.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Oncocytic IDC shares similarities with intercalated duct-like IDC. Although additional verification is needed, the oncocytic variant appears to be sufficiently unique to be now regarded as the fourth distinct subtype of IDC. Because of its indolent nature, oncocytic IDC should be distinguished from histological mimics.</AbstractText>
          <CopyrightInformation>© 2021 John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bishop</LastName>
            <ForeName>Justin A</ForeName>
            <Initials>JA</Initials>
            <Identifier Source="ORCID">0000-0002-0412-6810</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakaguro</LastName>
            <ForeName>Masato</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Whaley</LastName>
            <ForeName>Rumeal D</ForeName>
            <Initials>RD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ogura</LastName>
            <ForeName>Kanako</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Diagnostic Pathology, Juntendo University Nerima Hospital, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Imai</LastName>
            <ForeName>Hiroshi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Pathology Division, Mie University Hospital, Tsu, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Laklouk</LastName>
            <ForeName>Israa</ForeName>
            <Initials>I</Initials>
            <Identifier Source="ORCID">0000-0001-9688-3167</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Faquin</LastName>
            <ForeName>William C</ForeName>
            <Initials>WC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sadow</LastName>
            <ForeName>Peter M</ForeName>
            <Initials>PM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gagan</LastName>
            <ForeName>Jeffrey</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nagao</LastName>
            <ForeName>Toshitaka</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anatomical Pathology, Tokyo Medical University, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P01 CA240239</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>03</Month>
          <Day>31</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Histopathology</MedlineTA>
        <NlmUniqueID>7704136</NlmUniqueID>
        <ISSNLinking>0309-0167</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C511956">TRIM33 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D051096">Proto-Oncogene Proteins c-ret</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="C099282">RET protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="C482119">BRAF protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D048493">Proto-Oncogene Proteins B-raf</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D044584" MajorTopicYN="N">Carcinoma, Ductal</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002285" MajorTopicYN="Y">Carcinoma, Intraductal, Noninfiltrating</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017404" MajorTopicYN="N">In Situ Hybridization, Fluorescence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050596" MajorTopicYN="N">Oncogene Fusion</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024862" MajorTopicYN="N">Oxyphil Cells</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048493" MajorTopicYN="N">Proto-Oncogene Proteins B-raf</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051096" MajorTopicYN="N">Proto-Oncogene Proteins c-ret</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012468" MajorTopicYN="Y">Salivary Gland Neoplasms</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012469" MajorTopicYN="N">Salivary Glands</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017423" MajorTopicYN="N">Sequence Analysis, RNA</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">
NCOA4-RET
</Keyword>
        <Keyword MajorTopicYN="N">
TRIM33-RET
</Keyword>
        <Keyword MajorTopicYN="N">BRAF V600E</Keyword>
        <Keyword MajorTopicYN="N">intraductal carcinoma</Keyword>
        <Keyword MajorTopicYN="N">salivary gland neoplasms</Keyword>
      </KeywordList>
      <CoiStatement>Conflict of interest. The authors state that they have no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>25</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33135196</ArticleId>
        <ArticleId IdType="mid">NIHMS1722416</ArticleId>
        <ArticleId IdType="pmc">PMC8315294</ArticleId>
        <ArticleId IdType="doi">10.1111/his.14296</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Brandwein-Gensler M, Gnepp DR. Low-grade cribriform cystadenocarcinoma. In Barnes L, Eveson JW, Reichart P, Sidransky D eds. Pathology and genetics of head and neck tumours. World Health Organization classification of tumours. Lyon: IARC Press, 2005; 170–171.</Citation>
        </Reference>
        <Reference>
          <Citation>Brandwein-Gensler M, Hille J, Wang BY et al.Low-grade salivary duct carcinoma: description of 16 cases. Am. J. Surg. Pathol 2004; 28; 1040–1044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15252310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen KT. Intraductal carcinoma of the minor salivary gland. J. Laryngol. Otol 1983; 97; 189–191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6298331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Delgado R, Klimstra D, Albores-Saavedra J. Low grade salivary duct carcinoma. A distinctive variant with a low grade histology and a predominant intraductal growth pattern. Cancer 1996; 78; 958–967.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8780532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loening T, Leivo I, Simpson RHW, Weinreb I. Intraductal carcinoma. In El-Naggar A, Chan JK, Grandis JR, Takata T, Slootweg PJ eds. World Health Organization classification of head and neck tumours. Lyon: IARC Press, 2017; 170–171.</Citation>
        </Reference>
        <Reference>
          <Citation>Bishop JA, Gagan J, Krane JF, Jo VY. Low-grade apocrine intraductal carcinoma: expanding the morphologic and molecular spectrum of an enigmatic salivary gland tumor. Head Neck Pathol. 2020; 14; 869–875.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7669952</ArticleId>
            <ArticleId IdType="pubmed">31989433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guilmette J, Dias-Santagata D, Nose V, Lennerz JK, Sadow PM. Novel gene fusions in secretory carcinoma of the salivary glands: enlarging the ETV6 family. Hum. Pathol 2019; 83; 50–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30130630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsieh MS, Lee YH, Jin YT, Kuo YJ. Clinicopathological study of intraductal carcinoma of the salivary gland, with emphasis on the apocrine type. Virchows Arch. 2020; 477; 581–592.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32383006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu H, Graham RP, Seethala R, Chute D. Intraductal carcinoma of salivary glands harboring TRIM27-RET fusion with mixed low grade and apocrine types. Head Neck Pathol. 2020; 14; 239–245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7021891</ArticleId>
            <ArticleId IdType="pubmed">30610524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skalova A, Ptakova N, Santana T et al.NCOA4-RET and TRIM27-RET are characteristic gene fusions in salivary intraductal carcinoma, including invasive and metastatic tumors: is ‘intraductal’ correct? Am. J. Surg. Pathol 2019; 43; 1303–1313.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31162284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skalova A, Vanecek T, Uro-Coste E et al.Molecular profiling of salivary gland intraductal carcinoma revealed a subset of tumors harboring NCOA4-RET and novel TRIM27-RET fusions: a report of 17 cases. Am. J. Surg. Pathol 2018; 42; 1445–1455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30045065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinreb I, Bishop JA, Chiosea SI et al.Recurrent RET gene rearrangements in intraductal carcinomas of salivary gland. Am. J. Surg. Pathol 2018; 42; 442–452.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5844775</ArticleId>
            <ArticleId IdType="pubmed">29443014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinreb I, Tabanda-Lichauco R, Van der Kwast T, Perez-Ordonez B. Low-grade intraductal carcinoma of salivary gland: report of 3 cases with marked apocrine differentiation. Am. J. Surg. Pathol 2006; 30; 1014–1021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16861974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simpson RH, Desai S, Di Palma S. Salivary duct carcinoma in situ of the parotid gland. Histopathology 2008; 53; 416–425.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18983607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakaguro M, Urano M, Suzuki H et al.Low-grade intraductal carcinoma of the salivary gland with prominent oncocytic change: a newly described variant. Histopathology 2018; 73; 314–320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29574881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bishop JA, Gagan J, Baumhoer D et al.Sclerosing polycystic ‘adenosis’ of salivary glands: a neoplasm characterized by PI3K pathway alterations more correctly named sclerosing polycystic adenoma. Head Neck Pathol. 2020; 14; 630–636.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7413933</ArticleId>
            <ArticleId IdType="pubmed">31605313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haas BJ, Dobin A, Li B, Stransky N, Pochet N, Regev A. Accuracy assessment of fusion transcript detection via read-mapping and de novo fusion transcript assembly-based methods. Genome Biol. 2019; 20; 213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6802306</ArticleId>
            <ArticleId IdType="pubmed">31639029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rooper LM, Thompson LDR, Gagan J, Oliai BR, Weinreb I, Bishop JA. Salivary intraductal carcinoma arising within intra-parotid lymph node: a report of 4 cases with identification of a novel STRN-ALK fusion. Head Neck Pathol. 2020. E-pub ahead of print, 13July. 10.1007/s12105-020-01198-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12105-020-01198-0</ArticleId>
            <ArticleId IdType="pmc">PMC8010048</ArticleId>
            <ArticleId IdType="pubmed">32661669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bishop JA, Rooper LM, Sangoi AR, Gagan J, Thompson LDR, Inagaki H. The myoepithelial cells of salivary intercalated duct-type intraductal carcinoma are neoplastic: a study using combined whole-slide imaging, immunofluorescence, and RET fluorescence in situ hybridization. Am. J. Surg. Pathol 2020. E-pub ahead of print, 20October. 10.1097/PAS.0000000000001605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PAS.0000000000001605</ArticleId>
            <ArticleId IdType="pubmed">33086236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia JJ, Hunt JL, Weinreb I et al.Fluorescence in situ hybridization for detection of MAML2 rearrangements in oncocytic mucoepidermoid carcinomas: utility as a diagnostic test. Hum. Pathol 2011; 42; 2001–2009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21777943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinreb I, Seethala RR, Perez-Ordonez B, Chetty R, Hoschar AP, Hunt JL. Oncocytic mucoepidermoid carcinoma: clinicopathologic description in a series of 12 cases. Am. J. Surg. Pathol 2009; 33; 409–416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18971778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skalova A Mammary analogue secretory carcinoma of salivary gland origin: an update and expanded morphologic and immunohistochemical spectrum of recently described entity. Head Neck Pathol. 2013; 7(Suppl. 1); S30–S36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3712092</ArticleId>
            <ArticleId IdType="pubmed">23821207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skalova A, Baneckova M, Thompson LDR et al.Expanding the molecular spectrum of secretory carcinoma of salivary glands with a novel VIM-RET fusion. Am. J. Surg. Pathol 2020; 44; 1295–1307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32675658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang K, Russell JS, McDermott JD et al.Profiling of 149 salivary duct carcinomas, carcinoma ex pleomorphic adenomas, and adenocarcinomas, not otherwise specified reveals actionable genomic alterations. Clin. Cancer Res 2016; 22; 6061–6068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27334835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hatakeyama S TRIM family proteins: roles in autophagy, immunity, and carcinogenesis. Trends Biochem. Sci 2017; 42; 297–311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28118948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drilon A, Wang L, Hasanovic A et al.Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 2013; 3; 630–635.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4160032</ArticleId>
            <ArticleId IdType="pubmed">23533264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rabes HM, Demidchik EP, Sidorow JD et al.Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-Chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin. Cancer Res 2000; 6; 1093–1103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10741739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalin MG, Desrichard A, Katabi N et al.Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer. Clin. Cancer Res 2016; 22; 4623–4633.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5026550</ArticleId>
            <ArticleId IdType="pubmed">27103403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiosea SI, Williams L, Griffith CC et al.Molecular characterization of apocrine salivary duct carcinoma. Am. J. Surg. Pathol 2015; 39; 744–752.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25723113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gargano SM, Senarathne W, Feldman R et al.Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling. Cancer Med. 2019; 8; 7322–7329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6885888</ArticleId>
            <ArticleId IdType="pubmed">31609094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsieh MS, Bishop JA, Wang YP et al.Salivary sialadenoma papilliferum consists of two morphologically, immunopheno-typically, and genetically distinct subtypes. Head Neck Pathol. 2020; 14; 489–496.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7235136</ArticleId>
            <ArticleId IdType="pubmed">31473937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakaguro M, Urano M, Ogawa I et al.Histopathological evaluation of minor salivary gland papillary-cystic tumours: focus on genetic alterations in sialadenoma papilliferum and intraductal papillary mucinous neoplasm. Histopathology 2020; 76; 411–422.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31505033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skalova A, Vanecek T, Sima R et al.Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am. J. Surg. Pathol 2010; 34; 599–608.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20410810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Urano M, Nakaguro M, Yamamoto Y et al.Diagnostic significance of HRAS mutations in epithelial-myoepithelial carcinomas exhibiting a broad histopathologic spectrum. Am. J. Surg. Pathol 2019; 43; 984–994.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30994537</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
